Oxular
Rafiq is the CEO of EXACT Therapeutics, a clinical-stage Anglo-Norwegian biotech company. An MD by training, Rafiq has 25 years in the pharma industry globally. As Senior Vice President and Global Head of Ophthalmology at Bayer, he grew the business of Eylea® from launch to over $2.5bn in five years, including its launch in five indications in three years.
This person is not in the org chart
This person is not in any offices
Oxular
Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye.